| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M Sanson, L Bueno, J Fioramont. Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. vol 18. issue 10. 2006-10-30. PMID:16961698. |
activation of cannabinoid cb1 and cb2 receptors is known to attenuate nociception and hyperalgesia in somatic inflammatory conditions. |
2006-10-30 |
2023-08-12 |
rat |
| Clementina Manera, Veronica Benetti, M Paola Castelli, Tiziana Cavallini, Sara Lazzarotti, Fabio Pibiri, Giuseppe Saccomanni, Tiziano Tuccinardi, Alfredo Vannacci, Adriano Martinelli, Pier Luigi Ferrarin. Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists. Journal of medicinal chemistry. vol 49. issue 20. 2006-10-27. PMID:17004710. |
on the basis of docking studies carried out using the recently published cannabinoid receptor models,35 new 1,8-naphthyridin-4(1h)-on-3-carboxamide and quinolin-4(1h)-on-3-carboxamide derivatives were designed, synthesized, and tested for their affinities toward the cannabinoid cb1 and cb2 receptors. |
2006-10-27 |
2023-08-12 |
human |
| Steven W Paugh, Michael P Cassidy, Hengjun He, Sheldon Milstien, Laura J Sim-Selley, Sarah Spiegel, Dana E Selle. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor. Molecular pharmacology. vol 70. issue 1. 2006-10-24. PMID:16571654. |
we now report that both fty720 and sphingosine interact with cb1 but not cb2 cannabinoid receptors. |
2006-10-24 |
2023-08-12 |
mouse |
| Cheryl E Rockwell, Natasha T Snider, Jerry T Thompson, John P Vanden Heuvel, Norbert E Kaminsk. Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. Molecular pharmacology. vol 70. issue 1. 2006-10-24. PMID:16611855. |
2-arachidonyl glycerol (2-ag) is an endogenous arachidonic acid derivative that binds cannabinoid receptors cb1 and cb2 and is hence termed an endocannabinoid. |
2006-10-24 |
2023-08-12 |
mouse |
| Juan Pablo Prestifilippo, Javier Fernández-Solari, Carolina de la Cal, María Iribarne, Angela M Suburo, Valeria Rettori, Samuel M McCann, Juan Carlos Elverdi. Inhibition of salivary secretion by activation of cannabinoid receptors. Experimental biology and medicine (Maywood, N.J.). vol 231. issue 8. 2006-10-24. PMID:16946411. |
the best-known endocannabinoid is anandamide (aea), which binds with high affinity to cb1 and cb2. |
2006-10-24 |
2023-08-12 |
rat |
| Barbara Costa, Dario Siniscalco, Anna Elisa Trovato, Francesca Comelli, Maria Luisa Sotgiu, Mariapia Colleoni, Sabatino Maione, Francesco Rossi, Gabriella Giagnon. AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. British journal of pharmacology. vol 148. issue 7. 2006-10-05. PMID:16770320. |
antagonists at cannabinoid cb1 or cb2 receptors, or at the transient receptor potential vanilloid type 1 receptor, each partially reversed effects induced by am404. |
2006-10-05 |
2023-08-12 |
rat |
| b' A Sulcov\\xc3\\xa. [Impact of endocannabinoid system in modulation of cardiometabolic risk factors]. Vnitrni lekarstvi. vol 52. issue 6. 2006-10-03. PMID:16871766.' |
endocannabinoid system, the complex of specific cannabinoid receptors (cb1 and cb2 subtypes) and their endogenous agonistic ligands (endocannabinoids) plays, besides others, an important role in the central and peripheral regulation of food intake, fat accumulation, and lipid and glucose metabolism. |
2006-10-03 |
2023-08-12 |
human |
| Shigemi Yoshihara, Hiroshi Morimoto, Makoto Ohori, Yumi Yamada, Toshio Abe, Osamu Arisak. Cannabinoid receptor agonists inhibit Ca(2+) influx to synaptosomes from rat brain. Pharmacology. vol 76. issue 4. 2006-09-27. PMID:16446560. |
only a cannabinoid cb1 antagonist, [n-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1h-pyrazole-3-carboxamidehydrochloride] (sr 141716a), reversed the inhibitory effect of these win 55212-2 and anandamide on (45)ca(2+) uptake in rat synaptosomes, but not a cannabinoid cb2 receptor antagonist, [n-[(1s)-endo-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)pyrazole-3-carboxamide] (sr 144528). |
2006-09-27 |
2023-08-12 |
rat |
| David Fernández-López, José Martínez-Orgado, Estefanía Nuñez, Julián Romero, Pedro Lorenzo, Maria Angeles Moro, Ignacio Lizasoai. Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats. Pediatric research. vol 60. issue 2. 2006-09-25. PMID:16864698. |
ogd slices were incubated with vehicle or with the cb1/cb2 cannabinoid agonist win55212 (50 microm), the cb1 agonist arachidonyl-2-chloroethylamide (acea) (50 microm), or the cb2 agonist jw133 (50 microm), alone or combined with the cb1 and cb2 receptor antagonist sr 141716 (50 microm) or sr 144528 (50 microm), respectively. |
2006-09-25 |
2023-08-12 |
rat |
| J Singh, S Budhiraj. Therapeutic potential of cannabinoid receptor ligands: current status. Methods and findings in experimental and clinical pharmacology. vol 28. issue 3. 2006-09-11. PMID:16810344. |
there are at least two types of cannabinoid receptors, cb1 also named cnr1 and cb2 also named cnr2, both coupled to g proteins. |
2006-09-11 |
2023-08-12 |
Not clear |
| Janka Held-Feindt, Lutz Dörner, Gülcan Sahan, H Maximilian Mehdorn, Rolf Mentlei. Cannabinoid receptors in human astroglial tumors. Journal of neurochemistry. vol 98. issue 3. 2006-09-08. PMID:16893424. |
these effects have been claimed to be mediated via cannabinoid receptors 1 and 2 (cb1, cb2). |
2006-09-08 |
2023-08-12 |
human |
| Fatima Teixeira-Clerc, Boris Julien, Pascale Grenard, Jeanne Tran Van Nhieu, Vanessa Deveaux, Liying Li, Valérie Serriere-Lanneau, Catherine Ledent, Ariane Mallat, Sophie Lotersztaj. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nature medicine. vol 12. issue 6. 2006-09-07. PMID:16715087. |
we recently showed that activation of hepatic cannabinoid cb2 receptors limits progression of experimental liver fibrosis. |
2006-09-07 |
2023-08-12 |
mouse |
| Susanna M Saario, Antti Poso, Risto O Juvonen, Tomi Järvinen, Outi M H Salo-Ahe. Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system. Journal of medicinal chemistry. vol 49. issue 15. 2006-08-31. PMID:16854070. |
the endocannabinoid system consists of two cannabinoid receptors (cb1 and cb2), endogenous ligands (endocannabinoids), and the enzymes involved in the metabolism of the endocannabinoids, including fatty acid amide hydrolase (faah) and monoglyceride lipase (mgl). |
2006-08-31 |
2023-08-12 |
human |
| Matthew J McFarland, Ekaterina A Terebova, Eric L Barke. Detergent-resistant membrane microdomains in the disposition of the lipid signaling molecule anandamide. The AAPS journal. vol 8. issue 1. 2006-08-18. PMID:16584138. |
the endogenous cannabinoid anandamide is an agonist of the cannabinoid receptors cb1 and cb2, as well as transient receptor potential vanilloid type 1 and type 4 ion channels. |
2006-08-18 |
2023-08-12 |
Not clear |
| Ken Mackie, Nephi Stell. Cannabinoid receptors and endocannabinoids: evidence for new players. The AAPS journal. vol 8. issue 2. 2006-08-11. PMID:16796380. |
here we review the evidence suggesting that cannabinoids can modulate synaptic transmission, the cardiovascular system, and the immune system through receptors distinct from cb1 and cb2, and that an additional "independent" endocannabinoid signaling system that involves palmitoylethanolamide may exist. |
2006-08-11 |
2023-08-12 |
Not clear |
| Blanca Herrera, Arkaitz Carracedo, María Diez-Zaera, Teresa Gómez del Pulgar, Manuel Guzmán, Guillermo Velasc. The CB2 cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway. Experimental cell research. vol 312. issue 11. 2006-08-04. PMID:16624285. |
delta9-tetrahydrocannabinol and other cannabinoids exert pro-apoptotic actions in tumor cells via the cb2 cannabinoid receptor. |
2006-08-04 |
2023-08-12 |
human |
| Blanca Herrera, Arkaitz Carracedo, María Diez-Zaera, Teresa Gómez del Pulgar, Manuel Guzmán, Guillermo Velasc. The CB2 cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway. Experimental cell research. vol 312. issue 11. 2006-08-04. PMID:16624285. |
cannabinoid treatment led to a cb2 receptor-dependent stimulation of ceramide biosynthesis and inhibition of this pathway prevented delta9-tetrahydrocannabinol-induced mitochondrial hypopolarization and cytochrome c release, indicating that ceramide acts at a pre-mitochondrial level. |
2006-08-04 |
2023-08-12 |
human |
| K A Takahashi, P E Castill. The CB1 cannabinoid receptor mediates glutamatergic synaptic suppression in the hippocampus. Neuroscience. vol 139. issue 3. 2006-08-03. PMID:16527424. |
of the two cloned cannabinoid receptors, cannabinoid receptor 1 (cb1) is widely distributed in the cns and accounts for most of the neurological effects of cannabinoids, while cannabinoid receptor 2 (cb2) expression in the cns is very limited. |
2006-08-03 |
2023-08-12 |
mouse |
| K A Takahashi, P E Castill. The CB1 cannabinoid receptor mediates glutamatergic synaptic suppression in the hippocampus. Neuroscience. vol 139. issue 3. 2006-08-03. PMID:16527424. |
cannabinoid receptor 3 (cb3)] is suggested by growing evidence of cannabinoid effects that are not mediated by cb1 or cb2. |
2006-08-03 |
2023-08-12 |
mouse |
| Seishi Kishimoto, Saori Oka, Maiko Gokoh, Takayuki Sugiur. Chemotaxis of human peripheral blood eosinophils to 2-arachidonoylglycerol: comparison with other eosinophil chemoattractants. International archives of allergy and immunology. vol 140 Suppl 1. 2006-08-03. PMID:16772720. |
2-arachidonoylglycerol (2-ag), an endogenous ligand for the cannabinoid receptors (cb1 and cb2), has been shown to exhibit a variety of cannabimimetic activities in vitro and in vivo. |
2006-08-03 |
2023-08-12 |
human |